Consult a healthcare professional before using this product if you are pregnant, nursing, under 18 years of age, taking medication, or have a medical condition
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists, introduced in 2005, have become crucial in managing type 2 diabetes mellitus (T2DM) by regulating gastrointestinal motility and metabolic disorders
Malabsorption issues, such as gastrointestinal conditions
The primary end point was steroid use, with secondary end points including all-cause hospitalization, Crohns diseaserelated surgery, and persistence with advanced inflammatory bowel disease (IBD) therapy
melena: Whats the difference